COMMUNIQUÉS West-GlobeNewswire

Auxly Announces Receipt of Dealer’s Licence for Dosecann Facility

09/08/2018 - 13:00

VANCOUVER, British Columbia, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V:XLY) (" Auxly " or the " Company ") is pleased to announce that the Company’s wholly-owned subsidiary, Dosecann Inc. (“ [...]

ContraFect Announces Second Quarter 2018 Financial Results

09/08/2018 - 13:00

YONKERS, N.Y., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ContraFect Corporation (Nasdaq:CFRX), a clinical-stage biotechnology company focused on the discovery and development of protein and antibody therapeutics for life- [...]

Protalix BioTherapeutics Reports 2018 Second Quarter Results and Provides Corporate Update

09/08/2018 - 13:00

CARMIEL, Israel, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic [...]

Neuralstem Announces NSI-189 Granted Orphan Drug Designation from the U.S. FDA for the Treatment of Angelman Syndrome

09/08/2018 - 13:00

GERMANTOWN, Md., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on the development of nervous system therapies based on its neural stem cell technology, today [...]

Idera Pharmaceuticals To Present at the 2018 Wedbush PacGrow Healthcare Conference

09/08/2018 - 13:00

EXTON, Pa., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a pharmaceutical company focused on the development and commercialization of its proprietary immune modulator, tilsotolimod, for [...]

Pieris Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update

09/08/2018 - 13:00

COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON THURSDAY, AUGUST 9, 2018 AT 8:00 AM EDT BOSTON, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) , a clinical-stage biotechnology company [...]

Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

09/08/2018 - 13:00

- Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - - New Drug Application submissions expected in Q4 2018 - [...]

Ogilvy CommonHealth Worldwide continues growth with promotions and new hires

09/08/2018 - 13:00

PARSIPPANY, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Ogilvy CommonHealth Worldwide ( www.ogilvychww.com ), a WPP Health & Wellness company (NYSE: WPP) ( www.wpp.com ), announced five promotions and two new hires [...]

INSYS Therapeutics Appoints Elizabeth Bohlen to Board of Directors

09/08/2018 - 13:00

PHOENIX, Aug. 09, 2018 (GLOBE NEWSWIRE) -- INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of pharmaceutical cannabinoids and spray technology, today announced the [...]

Loxo Oncology Reports Second Quarter 2018 Financial Results

09/08/2018 - 12:45

- LOXO-292 New Drug Application (NDA) Submission to FDA Expected in Late 2019 - - Updated Larotrectinib Duration of Response Data to be Reported at ESMO - - Larotrectinib NDA PDUFA date is November 26, 2018 - STAMFORD, [...]

HEXO Harvests First Plants in 250,000 sq. ft. Greenhouse Expansion

09/08/2018 - 12:30

GATINEAU, Quebec, Aug. 09, 2018 (GLOBE NEWSWIRE) -- The Hydropothecary Corporation (“HEXO” or the “Company”) (TSX:HEXO) continues to execute on its aggressive expansion at its Gatineau campus, with the first harvest of [...]

Récolte de premières plantes dans la serre agrandie de 250 000 pi2 d’HEXO

09/08/2018 - 12:30

GATINEAU, Québec, 09 août 2018 (GLOBE NEWSWIRE) -- La société Hydropothecary (« HEXO » ou la « Société ») (TSX: HEXO) poursuit une formidable expansion sur son campus de Gatineau, avec une toute première récolte dans sa [...]

Histogenics Corporation Announces Second Quarter 2018 Financial and Operating Results

09/08/2018 - 12:30

‒ Top-line Superiority Data from NeoCart ® Phase 3 Clinical Trial on Track for Third Quarter of 2018 ‒ ‒ Initiation of Phase 3 Clinical Trial in Japan Expected in Second Half of 2018 ‒ ‒ Expansion of Management Team in [...]

Jounce Therapeutics Reports Second Quarter 2018 Financial Results

09/08/2018 - 12:30

- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data for JTX-2011 at the [...]

Clementia Reports Second Quarter 2018 Operating Results and Pipeline Updates

09/08/2018 - 12:30

Patient Enrollment in Phase 3 MOVE Trial of Palovarotene for FOP On Track; Two Interim Data Analyses Expected in 2019 MONTREAL, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Clementia Pharmaceuticals Inc. (NASDAQ: CMTA), a clinical [...]

Clementia présente ses résultats d’exploitation pour le deuxième trimestre de 2018 et fait le point sur son portefeuille de produits

09/08/2018 - 12:30

Le recrutement des patients pour l’essai de phase 3 MOVE sur le palovarotène pour le traitement de la fibrodysplasie ossifiante progressive (FOP) est sur la bonne voie; deux analyses intérimaires des données sont [...]

Emergent BioSolutions to Acquire Specialty Vaccines Company PaxVax

09/08/2018 - 12:30

Adds two revenue-generating FDA-licensed vaccines that protect against cholera and typhoid fever, both with dual-market potential Broadens development pipeline with an adenovirus 4/7 vaccine funded by the DoD for [...]

Cerecor Reports Second Quarter 2018 Financial Results

09/08/2018 - 12:30

BALTIMORE, Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ: CERC), an integrated biopharmaceutical company focused on pediatric healthcare and developing innovative therapies that make a difference in the lives [...]

RadNet Reports Second Quarter Financial Results to Include Record Revenue and Reaffirms Guidance Ranges

09/08/2018 - 12:00

Total Net Revenue increased 6.3% to $244.4 million in the second quarter of 2018 from $230.0 million in the second quarter of 2017 Adjusted EBITDA (1) increased 3.0% to $38.2 million in the second quarter of 2018 from $ [...]